Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partnrs from a "hold" rating to a "strong-buy" rating.
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $160.00 price target on the stock.
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Spruce Biosciences (NASDAQ:SPRB) was upgraded by analysts at
Wall Street
Spruce Biosciences (NASDAQ:SPRB) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.